Investors
News Releases
- October 3, 2024Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
- October 2, 2024Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
- September 30, 2024Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
- September 5, 2024Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
- August 15, 2024Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
- August 6, 2024Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
- July 24, 2024Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
- July 16, 2024Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
- July 9, 2024Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
- July 2, 2024Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
Events & Presentations
-
Annovis Bio - Phase III PD Data
-
AD & PD Data Updates - July 2024
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top